Literature DB >> 10413275

Redefining the HIV-infectious window period in the chimpanzee model: evidence to suggest that viral nucleic acid testing can prevent blood-borne transmission.

K K Murthy1, D R Henrard, J W Eichberg, K E Cobb, M P Busch, J P Allain, H J Alter.   

Abstract

BACKGROUND: Although it is rare, blood-transmitted HIV infection can occur when a donor presents in the window period between HIV-1 exposure and the first appearance of detectable p24 antigen. STUDY DESIGN AND METHODS: To study this seronegative window period, a chimpanzee (X034) was inoculated with 38 median tissue culture infective doses of HIV-1 IIIB; serum and peripheral blood mononuclear cells were obtained one to two times per week for 12 weeks and then biweekly for 12 weeks. Infectivity was monitored by the detection of serum HIV RNA, cell-associated HIV DNA, p24 antigen, and anti-HIV and by co-culture methods.
RESULTS: No HIV markers were noted until 5 weeks after inoculation, at which time virus was isolated and HIV RNA and DNA were detected in plasma and cells, respectively. Anti-HIV and HIV p24 antigen were not present until 8 weeks after inoculation. Plasma and cells obtained from Chimpanzee X034 3 or 4 weeks after exposure were then sequentially inoculated into a second chimpanzee (X176); no HIV infection was observed in this animal during serial follow-up for 24 weeks after each inoculation. In contrast, when the fifth-week HIV-1 RNA- and DNA-positive sample was inoculated, Chimpanzee X176 was unequivocally infected with HIV-1.
CONCLUSIONS: Nucleic acid testing narrowed the seronegative window by 3 weeks (37%). More important, there was no demonstrable infectivity in either plasma or peripheral blood mononuclear cells obtained before molecular markers were detectable. This suggests that the infectious window may be considerably shorter than the total window as measured from exposure and that nucleic acid testing might not only shorten the seronegative window, but totally prevent transfusion-transmitted HIV infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10413275     DOI: 10.1046/j.1537-2995.1999.39070688.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  8 in total

1.  Contribution of combined detection assays of p24 antigen and anti-human immunodeficiency virus (HIV) antibodies in diagnosis of primary HIV infection by routine testing.

Authors:  T D Ly; C Edlinger; A Vabret
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  Blood screening by nucleic acid amplification technology: current issues, future challenges.

Authors:  J L Gallarda; E Dragon
Journal:  Mol Diagn       Date:  2000-03

3.  Multicenter evaluation of a new automated fourth-generation human immunodeficiency virus screening assay with a sensitive antigen detection module and high specificity.

Authors:  Bernard Weber; Lutz Gürtler; Rigmor Thorstensson; Ulrike Michl; Annelies Mühlbacher; Philippe Bürgisser; Roberto Villaescusa; Adolfo Eiras; Christian Gabriel; Herbert Stekel; Srivilai Tanprasert; Sinenaart Oota; Maria-Jose Silvestre; Cristina Marques; Maria Ladeira; Holger Rabenau; Annemarie Berger; Urban Schmitt; Walter Melchior
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

4.  TaqMan 5'-nuclease human immunodeficiency virus type 1 PCR assay with phage-packaged competitive internal control for high-throughput blood donor screening.

Authors:  C Drosten; E Seifried; W K Roth
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

5.  Evaluation of a new combined antigen and antibody human immunodeficiency virus screening assay, VIDAS HIV DUO Ultra.

Authors:  Bernard Weber; Annemarie Berger; Holger Rabenau; Hans Wilhelm Doerr
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

6.  False-positive human immunodeficiency virus antibody test in a dialysis patient.

Authors:  Douglas M Silverstein; Diego H Aviles; V Matti Vehaskari
Journal:  Pediatr Nephrol       Date:  2004-02-26       Impact factor: 3.714

7.  High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection.

Authors:  Zhong-Min Ma; Mars Stone; Mike Piatak; Becky Schweighardt; Nancy L Haigwood; David Montefiori; Jeffrey D Lifson; Michael P Busch; Christopher J Miller
Journal:  J Virol       Date:  2009-01-07       Impact factor: 5.103

8.  Nucleic acid testing: Is it the only answer for safe Blood in India?

Authors:  N K Naidu; Z S Bharucha; Vandana Sonawane; Imran Ahmed
Journal:  Asian J Transfus Sci       Date:  2016 Jan-Jun
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.